Leios Therapeutics Partners with BNC Korea for 10XB-101 Fat Reduction Treatment Development
核心洞察
Leios Therapeutics (搜索) has entered a strategic licensing agreement with BNC Korea (搜索) for 10XB-101, an investigational injectable treatment for focal fat reduction and body contouring.
Phase 2b trial results showed 64% and 70% of patients in higher dose groups achieved grade 2 or greater improvement in submental fat (搜索) reduction scales compared to 0% on placebo.
The partnership grants BNC Korea (搜索) development and commercialization rights across nine territories including South Korea, Taiwan, Singapore, and other Asian markets.
Leios Therapeutics (搜索), a clinical-stage biotechnology company focused on aesthetic therapies, announced a strategic licensing agreement with BNC Korea (搜索) for its investigational fat reduction treatment 10XB-101. The partnership includes both licensing rights and a strategic equity investment from BNC Korea, a leading healthcare and aesthetics company listed on KOSDAQ.
Clinical Trial Results Drive Partnership
The collaboration is anchored by compelling Phase 2b trial data for 10XB-101 in submental fat (搜索) reduction. According to Choi Wan-gyo, CEO of BNC Korea (搜索), the study demonstrated that 64% and 70% of completers in higher dose groups (3.0% and 4.5%) achieved grade 2 or greater improvement in both clinician and patient submental fat scales (CSFS and PSFS) compared to 0% on placebo as part of patient reported outcome assessments. The treatment also exhibited what BNC Korea characterized as a "pristine safety profile."
"We are pleased to partner with Leios Therapeutics (搜索) on 10XB-101, a promising candidate in the rapidly expanding body contouring market," said Choi Wan-gyo. "We believe this product has the potential to address unmet needs in focal fat treatment."
Territorial Rights and Market Expansion
Under the licensing agreement, BNC Korea (搜索) has secured rights to develop and commercialize 10XB-101 across nine territories: South Korea, Taiwan, Singapore, Indonesia, Thailand, Vietnam, Russia, Belarus, and Kazakhstan. This geographic scope positions the partnership to address the growing aesthetic medicine market across key Asian and Eastern European regions.
Ted White, Chief Executive Officer of Leios Therapeutics (搜索), emphasized the strategic value of the partnership: "BNC Korea (搜索)'s leadership in the aesthetics market, deep regional expertise, and outstanding commercialization capabilities make them an ideal partner to help bring 10XB-101 to market. The strategic investment further validates the potential of our pipeline, strengthens our balance sheet and supports the advancement of our clinical development program and long-term growth strategy."
Treatment Profile and Development Status
10XB-101 is being developed as a minimally invasive injectable treatment designed to reduce focal fat deposits (搜索) and enhance body contouring outcomes. Leios Therapeutics (搜索) has completed Phase 2 trials in submental fat (搜索) reduction indication, positioning the treatment as what the company describes as a "best-in-class" option in the focal fat reduction space.
BNC Korea (搜索) brings significant expertise to the partnership as a manufacturer of dermal fillers specializing in wrinkle improvement fillers and adhesion prevention products. Founded in 2007 and based in Daegu, South Korea, the company focuses on processing biomaterials such as hyaluronic acid and collagen for medical devices, pharmaceuticals, and cosmeceutical products.
Vault Advisors (搜索) served as the exclusive financial advisor to Leios Therapeutics (搜索) in structuring the transaction, which represents a significant milestone for the clinical-stage biotechnology company as it advances its aesthetic therapy pipeline.